Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck launches Lexapro in Japan

Danish pharmaceutical company Lundbeck is to launch its antidepressant Lexapro (escitalopram oxalate) in Japan

Danish pharmaceutical company Lundbeck is to launch its antidepressant Lexapro (escitalopram oxalate) in Japan.

The drug will be co-marketed in the country by Lundbeck and Japanese pharmaceutical firm Mochida, following an agreement made in January 2010.

Financial terms of the deal have not been disclosed, but Lundbeck is due to receive regulatory milestone payments and royalties on sales.

Lexapro was approved following clinical phase III studies in Japan that confirmed its efficacy and tolerability.

The companies say they estimate sales of Lexapro amounting to 3bn Yen for the first year following the launch and 33.8bn Yen during 2018 when revenue will be at its peak.

22nd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics